

**SELECTED PHARMACEUTICALS IN LATE STAGE U.S. AND E.U. DEVELOPMENT OR REGISTRATION as of 4/14/20**

Therapeutic Area	Product Name	Indication Sought	U.S. Development Stage	E.U. Development Stage	
Cardiovascular and Metabolism	XARELTO® (rivaroxaban)	Infrainguinal revascularized PAD (2) Pediatric VTE (2)	Phase III Phase III		
	INVOKANA® (canagliflozin) apocritentan	Treatment of Diabetic Kidney Disease in adults with T2DM (2) Difficult to treat hypertension (2)	Approved 9/19 Phase III	Filed 7/19 Phase III	
Immunology	TREMFYA® (guselkumab)	Psoriatic arthritis Crohn's Disease Pediatric Psoriasis	Filed 9/19 Phase IIB/III Phase III	Filed 10/19 Phase IIB/III Phase III	
	SIMPONI® SIMPON ARIAI®	Pediatric Ulcerative Colitis Polyarticular Juvenile Idiopathic Arthritis (pJIA)	Phase III Phase III Filed 3/20	Phase III Phase III	
	STELARA® (ustekinumab)	Juvenile Psoriatic Arthritis (jPsA) Pediatric Psoriasis (6-11 year-olds) Lupus	Filed 3/20 Filed 9/19 Phase III	Approved 1/20 Phase III	
Infectious Diseases and Vaccines	Rilpivirine Long Acting nanosuspension for injection pimodivir (JNJ-3872) VAC52150 VAC89220	HIV Infection  Influenza A (2) Monovalent Ebola Virus Vaccine HIV Px Vaccine	Complete Response 12/19  Phase III Phase III Phase III	Filed 7/19  Phase III Filed 11/19 Phase III	
	SPRAVATO™ (esketamine) ponesimod paliperidone palmitate 6 month long-acting injectable	Major depressive disorder who have active suicidal ideation with intent Monotherapy for multiple sclerosis Treatment of Schizophrenia	Filed 10/19 Filed 3/20 Phase III	Filed 1/20 Filed 3/20 Phase III	
Oncology	DARZALEX®	Relapsed Refractory MM 1+ prior lines w/PomDex (2) Relapsed Refractory multiple myeloma w/carfilzomib/dex (Amgen sponsored) (2) Amyloidosis (AMY 3001) (2) Subcutaneous Formulation in patients with relapsed or refractory multiple myeloma (MMY3012, COLUMBA) (2) Smoldering multiple myeloma (SMM3001) (2) Frontline multiple myeloma transplant ineligible in combination w/ bortezomib, lenalidomide and dexamethasone (MMY3019, CEPHEUS) (2) Frontline multiple myeloma transplant eligible in combination w/ bortezomib, lenalidomide and dexamethasone (MMY3014, PERSEUS) (2)	Phase III Filed 2/20 Phase III Filed 7/19 Phase III Phase III	Phase III  Phase III Filed 7/19 Phase III Phase III	
	IMBRUVICA® (ibrutinib)	Treatment naive patients with Mantle Cell Lymphoma in combination with Bendamustine and Rituximab (randomized study MCL-3002) (2) Relapsed/refractory patients with Indolant Non-Hodgkins Lymphoma in combination with Bendamustine and Rituximab or R-CHOP; (randomized study FLR-3001) (2) Frontline Chronic Lymphocytic Leukemia in combination with Rituximab (Young and Fit) (ECOG 1912) (2)	Phase III Phase III Filed 11/19	Phase III Phase III Filed 1/20	
		Frontline Chronic Lymphocytic Leukemia in combination with venetoclax (fixed duration) (GLOW) (2) Frontline Chronic graft-versus-host-disease (cGVHD) (2) Relapsed/refractory patients with Mantle Cell Lymphoma in combination with venetoclax (PCYC-1143) (2)	Phase III Phase III Phase III	Phase III Phase III Phase III	
		ERLEADA® (apalutamide)	Metastatic castrate sensitive prostate cancer (TITAN) Localized prostate cancer High risk prostate cancer (PROTEUS)	Approved 9/19 Phase III Phase III Phase III	Approved 1/20 Phase III Phase III Phase III
		apalutamide/ abiraterone acetate BALVERSA™ (erdafitinib)	Prostate Cancer metastatic castration resistant chemotherapy naïve Urothelial cancer (2) Tumor Agnostic	Phase III Approved 4/19 Phase IIB Phase IIB Phase III	Phase III Phase III Phase IIB Phase IIB Phase III
	niraparib (PARP inhibitor) niraparib / abiraterone acetate	L3 Prostate cancer metastatic castration-resistant L1 Prostate cancer metastatic castration-resistant in combination with abiraterone acetate and Prednisone	Phase III Phase III	Phase III Phase III	
	BCMA CAR-T Amivantamab (EGFR/cMET) OPSUMIT®	Relapsed refractory multiple myeloma (2) Non Small Cell Lung Cancer Fontan-palliated in adolescent (>12 years old) and adult patients Pediatric pulmonary arterial hypertension	Phase II Phase II Phase III Phase III	Phase II Phase II Phase III Phase III	
	Pulmonary Hypertension	UPTRAVI®	Chronic thromboembolic pulmonary hypertension Pulmonary arterial hypertension IV	Complete Response 1/19 Phase III Phase III	Submission Withdrawn 11/19 Phase III Phase III
		Macitentan w/tadalafil FDC	Chronic thromboembolic pulmonary hypertension Pulmonary arterial hypertension	Phase III Phase III	Phase III Phase III

\* This information is accurate as of the date hereof to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information.

(2) INVOKANA licensed from Mitsubishi Tanabe Pharma Corporation; Long acting HIV injectable treatment regimen of rilpivirine and cabotegravir developed in collaboration with ViiV Healthcare Ltd; apocritentan developed in collaboration with Idorsia; XARELTO co-developed with Bayer HealthCare; paliperidone palmitate includes technology licensed from Alkermes, Inc.; DARZALEX licensed from Genmab A/S; IMBRUVICA developed in collaboration with Pharmacyclics, LLC, an AbbVie company; Pimodivir (JNJ-3872) licensed from Vertex Pharmaceuticals, Inc.; BALVERSA discovered in collaboration with Astex Pharmaceuticals, Inc.; Niraparib licensed from Tesaro; BCMA CAR-T licensed from Legend Biotech; Monovalent Ebola Vaccine developed in collaboration with Bavarian Nordic A/S, and MVA-BN-Filo® is licensed-in from Bavarian Nordic A/S.

**Janssen Pharmaceutical Companies of Johnson & Johnson**  
**Selected NME Pharmaceutical Pipeline - Recent Approvals/Potential Filings\***  
 Selective Highlights as of April 14, 2020

NMEs APPROVED 2019	NMEs IN REGISTRATION	NME PLANNED FILINGS 2020-2023*	
Oncology	Infectious Diseases & Vaccines	Oncology	Neuroscience
<b>ERLEADA® (apalutamide) (EU)</b> Non-metastatic prostate cancer  <b>BALVERSA™ (erdafitinib) (US)</b> Urothelial cancer	<b>Monovalent Ebola Vaccine (EU)</b> Ebola virus Disease	<b>Niraparib</b> Metastatic castration-resistant prostate cancer (mCRPC)  <b>BCMA CAR-T</b> Multiple Myeloma  <b>BALVERSA™ (erdafitinib) (EU)</b> Urothelial cancer  <b>Lazertinib</b> Non Small Cell Lung Cancer  <b>Cusatuzumab</b> Acute myeloid leukemia  <b>Amivantamab (EGFR/cMET)</b> Non Small Cell Lung Cancer  <b>JNJ-7957 (BCMA/CD3), JNJ-7564 (GPCR5D/CD3)</b> Multiple myeloma	<b>Seltorexant</b> Adjunctive treatment for major depressive disorder with insomnia symptoms
	Neuroscience		Infectious Diseases & Vaccines
	<b>Ponesimod</b> Monotherapy for multiple sclerosis		<b>Pimodivir</b> Influenza A  <b>RSV Sr vaccine</b> RSV vaccine
Neuroscience			Cardiovascular & Metabolism
<b>SPRAVATO™ (Esketamine)</b> Treatment resistant depression			<b>CNGB3 and CNGA3 AAV Gene Therapy</b> Achromatopsia  <b>RPGR AAV Gene Therapy</b> X-linked retinitis pigmentosa  <b>Aprocitentan</b> Difficult to treat hypertension
		Immunology	
		<b>JNJ-4500 Anti-NKG2D</b> Crohn's disease	

\*Filings/approvals assumed to be in the US and EU unless otherwise noted. This information is accurate as of the date hereof to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information. Pimodivir (JNJ-3872) licensed from Vertex Pharmaceuticals, Inc.; Niraparib licensed from Tesaro; BALVERSA discovered in collaboration with Astex Pharmaceuticals, Inc.; BCMA CAR-T licensed from Legend Biotech; Cusatuzumab licensed from Argenx; Lazertinib licensed from Yuhan Corporation; JNJ-4500 Anti-NKG2D licensed from Novo Nordisk; Retinal assets (Achromatopsia: AAV-CNGA3, AAV-CNGB3) and (X-Linked Retinitis Pigmentosa: AAV-RPGR) licensed from MeiraGTx; Seltorexant being developed in collaboration with Minerva Neurosciences; DUOBODY platform licensed from Genmab relates to several bispecific antibody programs (JNJ-6372, JNJ-7957, JNJ-7564); Monovalent Ebola Vaccine developed in collaboration with Bavarian Nordic A/S, and MVA-BN-Filo® is licensed-in from Bavarian Nordic A/S.

